Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
Launched by EISAI CO., LTD. · Jul 23, 2009
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Histologically or clinically confirmed diagnosis of advanced HCC.
- • 2. Eastern Cooperative Oncology Group-Performance Status (ECOG-PS): 0-1.
- • 3. Adequate laboratory values/organ function tests.
- Exclusion criteria:
- • 1. Simultaneous or metachronous cancers.
- • 2. Pericardial, ascites, or pleural effusion requiring drainage.
- • 3. Brain metastasis/meningeal carcinomatosis presenting clinical symptoms or requiring treatment.
- • 4. Malabsorption syndrome.
- • 5. Artery-portal vein shunt or artery-vein shunt preventing proper diagnosis of tumor.
- • 6. Use of drugs known to inhibit cytochrome P3A4.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a global pharmaceutical company headquartered in Japan, dedicated to the research, development, and commercialization of innovative therapeutics that address unmet medical needs. With a strong focus on neurology and oncology, Eisai leverages its extensive expertise in drug discovery and development to advance treatments that improve patient outcomes. Committed to the principles of transparency and collaboration, Eisai actively engages in clinical trials to evaluate the safety and efficacy of its products, ensuring that its research aligns with the highest ethical standards. Through its patient-centric approach, Eisai strives to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minato Ku, Tokyo, Japan
Sapporo Shi, Hokkaido, Japan
Kawasaki Shi, Kanagawa, Japan
Osaka Shi, Osaka, Japan
Chuo Ku, Tokyo, Japan
Kurume Shi, Fukuoka, Japan
Saga Shi, Saga, Japan
Kashiwa Shi, Chiba, Japan
Osakasayama Shi, Osaka, Japan
Musashino Shi, Tokyo, Japan
Gangnam Gu, Seoul, Korea, Republic Of
Songpa Gu, Seoul, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials